Recro pharma, inc. (REPH)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue

21,777

17,643

25,255

31,256

25,065

17,783

18,283

21,739

19,542

-

17,114

16,934

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Manufacturing, royalty and profit sharing revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16,933

17,138

-

16,120

16,704

-

-

-

-

-

-

-

-

-

Research and development revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

346

604

-

419

1,956

-

-

-

-

-

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

18,742

-

16,951

17,279

17,742

-

16,539

18,660

-

-

-

-

-

-

-

-

-

Operating expenses:
Cost of sales (excluding amortization of intangible assets)

18,254

11,463

11,027

14,100

14,391

12,127

8,472

12,071

10,490

10,365

6,882

10,448

10,498

11,589

5,745

9,547

10,271

-

10,039

9,395

-

-

-

-

-

-

-

-

-

Research and development

-

-

1,845

7,180

-

-25,545

11,348

10,157

8,442

-19,672

9,296

7,073

7,763

10,104

7,046

8,320

7,808

4,989

2,716

2,821

1,754

2,176

3,633

1,837

226

61

122

245

113

Selling, general and administrative

5,446

-

-

-

6,505

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

-

-

6,879

9,997

-

-

6,969

12,955

9,518

-

6,635

6,322

4,032

3,480

3,841

2,763

2,658

4,556

3,478

2,597

2,385

1,307

1,084

958

646

90

160

203

91

Amortization of intangible assets

646

645

646

646

646

645

646

646

646

645

646

646

646

645

646

646

646

-

646

592

-

-

-

-

-

-

-

-

-

Change in warrant valuation

-

1,178

160

1,041

-263

363

287

-1,139

773

-6

808

-1,084

291

-421

402

1,240

-1,594

-

-762

882

-

-

-

-

-

-

-

-

-

Change in contingent consideration valuation

-

-

3,909

-4,059

-

-

4,115

396

2,520

-

3,550

2,959

2,814

2,024

3,192

1,534

2,978

-

586

2,000

-

-

-

-

-

-

-

-

-

Total operating expenses

24,346

939

24,466

28,905

21,279

-34,446

31,837

35,086

32,389

-20,656

27,817

26,364

26,044

27,421

20,872

24,050

22,767

-

16,703

18,287

-

-

-

-

-

-

-

-

-

Operating income from continuing operations

-

-

-4,305

-2,837

-

58,337

-15,626

-15,422

-14,808

43,041

-11,876

-10,520

-8,380

-11,343

-5,361

-8,080

-6,528

-

-2,152

-1,311

-

-

-

-

-

-

-

-

-

Operating income (loss) from continuing operations

-2,569

-

789

2,351

3,786

-

-13,554

-13,347

-12,847

-

-10,703

-9,430

-7,302

-10,056

-3,921

-6,771

-5,025

-

-164

373

-

-

-

-

-

-

-

-

-

Total operating expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,139

3,484

4,718

2,795

873

152

283

448

205

Other income (expense):
Interest income

30

121

323

182

175

261

126

114

142

85

62

117

105

22

10

8

9

2

2

4

3

3

4

2

0

0

0

0

0

Grant income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Interest expense

5,153

5,254

5,417

5,370

3,765

2,266

2,198

2,189

2,103

8,409

1,235

1,207

1,183

1,309

1,450

1,317

1,512

-

1,990

1,688

-

0

0

0

4,272

231

220

212

203

Income tax expense

-

-

-

-

-

24,866

-2,370

-2,707

-2,353

12,096

-2,821

-1,665

-293

-941

18

-195

11

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) from continuing operations

-7,692

-

-

-

196

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on discontinued operations

-

-

-

-

-2,173

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

3

4

2

-4,272

-231

-220

-212

-203

Net loss

-7,692

-9,511

-4,305

-2,837

-1,977

-41,297

-13,256

-12,715

-12,455

-24,085

-9,055

-8,855

-8,087

-10,402

-5,379

-7,885

-6,539

-

-

-

-4,136

-3,480

-4,713

-2,793

-5,146

-383

-503

-661

-408

Per share information:
Net income (loss) per share from continuing operations, basic

-0.33

-

-

-

0.01

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share from discontinued operations, basic

-

-

-

-

-0.10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,270

113

110

112

104

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,152

-1,311

-4,136

-3,480

-4,713

-2,793

-6,416

-496

-614

-773

-513

Net loss per share of common stock, basic and diluted

-

-

-0.19

-0.13

-

-

-0.64

-0.62

-

-

-0.48

-

-0.42

-

-0.50

-

-0.71

-

-0.24

-0.17

-0.53

1.85

-0.61

-0.36

-3.67

-3.19

-3.95

-4.97

-3.30

Weighted average common shares outstanding, basic and diluted

-

-

22,505

22,265

-

-

20,721

20,410

-

-

19,058

-

19,049

-

10,780

-

9,251

-

9,118

7,829

7,768

7,789

7,707

7,707

1,749

155

155

155

155

Net loss per share, basic

-0.33

-

-

-

-0.09

-

-

-

-0.65

-

-

-0.46

-

-

-

-0.83

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average common shares outstanding, basic

23,394

-

-

-

21,918

-

-

-

19,219

-

-

19,052

-

-

-

9,544

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per share from continuing operations, diluted

-0.33

-

-

-

0.00

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share from discontinued operations, diluted

-

-

-

-

-0.10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share, diluted

-0.33

-

-

-

-0.10

-

-

-

-0.65

-

-

-0.48

-

-

-

-0.83

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average common shares outstanding, diluted

23,394

-

-

-

21,978

-

-

-

19,219

-

-

19,220

-

-

-

9,544

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-7,692

-9,511

-4,305

-2,837

-1,977

-41,297

-13,256

-12,715

-12,455

-24,085

-9,055

-8,855

-8,087

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other comprehensive loss:
Unrealized gain/(loss) on available-for-sale securities

-

-

-1

1

-1

-

-

1

-

7

68

-19

-57

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-7,692

-9,511

-4,305

-2,836

-1,978

-41,297

-13,256

-12,714

-12,455

-24,078

-8,987

-8,874

-8,144

-10,402

-5,379

-7,885

-6,539

-

-

-

-

-

-

-

-

-

-

-

-